HPGC Renmintongtai Pharmaceutical (600829) Fundamentals 2026 — P/E 38.2x, Revenue Analysis | SniperIQ
HPGC Renmintongtai Pharmaceutical (600829) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥5.2B, trading at ¥8.99 on the SHH. This SniperIQ fundamentals page covers HPGC Renmintongtai Pharmaceutical's valuation (P/E 38.2x, P/B 1.7x), profitability (net margin 1.3%), revenue (¥10.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is HPGC Renmintongtai Pharmaceutical's market cap?
HPGC Renmintongtai Pharmaceutical (600829) has a market capitalization of approximately ¥5.2B, trading at ¥8.99 on the SHH. Market cap moves with the live share price.
What is HPGC Renmintongtai Pharmaceutical's P/E ratio?
HPGC Renmintongtai Pharmaceutical's trailing twelve-month P/E ratio is 38.2x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is HPGC Renmintongtai Pharmaceutical?
HPGC Renmintongtai Pharmaceutical runs a net profit margin of 1.3%, a gross margin of 8.3%, and an operating margin of 1.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does HPGC Renmintongtai Pharmaceutical generate?
HPGC Renmintongtai Pharmaceutical reported revenue of ¥10.4B for fiscal year 2025, with net income of ¥134M and earnings per share (EPS) of 0.23. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does HPGC Renmintongtai Pharmaceutical pay a dividend?
HPGC Renmintongtai Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is HPGC Renmintongtai Pharmaceutical financially healthy?
HPGC Renmintongtai Pharmaceutical carries a debt-to-equity ratio of 0.24x and a current ratio of 1.66x, with a market beta of 0.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is HPGC Renmintongtai Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For HPGC Renmintongtai Pharmaceutical (600829) the key facts are: market cap ¥5.2B, P/E 38.2x, revenue ¥10.4B, 52-week range 7.54-18.13. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track HPGC Renmintongtai Pharmaceutical's full fundamentals live
Get HPGC Renmintongtai Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.